Ariosa Diagnostics, a molecular diagnostics company focused on prenatal testing, has chosen to use DSG's eCaseLink EDC (electronic data capture) system for the NEXT (Non-Invasive Chromosomal Examination of Trisomy) study.
“DSG is pleased to partner with Ariosa Diagnostics on their study. With the use of DSG's unique eCaseLink EDC system, we are confident in the successful outcome of the trial”
DSG's eCaseLink system captures study data electronically at the point of research, making data collection highly efficient. At any time throughout the study, clean, accurate data is available for review. DSG's eCaseLink allows Ariosa not only to collect and manage their data in real time, but also gives them the option of adding needed functionality as the study progresses.
Ariosa's NEXT study focuses on the non-invasive detection of fetal Trisomy 21 during the first trimester of pregnancy. Current methods of prenatal testing have drawbacks; invasive procedures can put both mother and fetus at risk, while conventional screening methods lack accuracy and can be difficult to implement. The NEXT study will compare the effectiveness of Ariosa's prenatal test against current standard first trimester screening for fetal Trisomy 21 detection.
"DSG is pleased to partner with Ariosa Diagnostics on their study. With the use of DSG's unique eCaseLink EDC system, we are confident in the successful outcome of the trial," says Tony Varano, CEO of DSG.
From womb to midlife: Prenatal immune disruptions reshape memory and cognitive aging